Picture EBD Group World of Partnering Opportunities 650x100px
Document › Details

T-Curx GmbH. (2/9/24). "Press Release: T-Curx Extends Its Management Team with Marion Jung, PhD, as Its New Chief Operating Officer".

Organisations Organisation T-Curx GmbH
  Organisation 2 ChromoTek GmbH
  Group Proteintech (Group)
Products Product CAR T-cell technology (Chimeric Antigen Receptor T-Cell technology)
  Product 2 Chromobody® cell line
  Index term 2 ChromoTek–Proteintech: investment, 202010 acquisition of ChromoTek by Proteintech Group
Persons Person Jung, Marion (T-Curx 202402– COO before ChromoTek Managing Director + Co-Founder + Earlybird Ventures)
  Person 2 Grawunder, Ulf (T-Curx 202210– CEO + Co-Founder before NBE Therapeutics + 4-Antibody)

Marion Jung, PhD, a seasoned Biotech executive, joins the management team of T-CURX as Chief Operations Officer (COO), complementing T-CURX management team with her strong track record in building Biotech companies and preparing them for future growth and commercial success

Today, T-CURX announces the appointment of Marion Jung, PhD, as the company’s new Chief Operating Officer. Marion brings a complete entrepreneurial skill set with her to T-CURX with her over 20 years of experience in building Biotech companies, most recently as co-founder and CEO of ChromoTek, a camelid nanobodies-based bioreagent company, which she has successfully build into a market leader in its segment since 2011. Marion successfully sold and integrated ChromoTek to the Proteintech Group in Illinois, USA. Beforehand, she was a Principal at Venture Capital firm Earlybird Ventures for 12 years, where she defined investment strategies, was deeply involved in the fund’s activities to finance innovative Biotech and Medical Device companies.

Ulf Grawunder, PhD, co-founder and CEO of T-CURX comments: «I am very excited and it is a privilege to have Marion at my side at T-CURX, as the new COO. Her strong track-record in successfully building and growing Biotech companies complements the experiences of our executive management team and myself for further strengthening the foundations of the company and preparing it for further growth and success.”

Marion comments: «It is an absolute priviledge to join this outstanding leadership team with extensive clinical and industry experience. T-CURX innovative CAR-T technologies and products addressing the needs of patients and the market alike, convinced me that the company has the right ingredients for future success. I am highly motivated to help the T-CURX team with my experience to further build and grow the company to fully unlock its enormous potential.»

Marion is a molecular biologist by training with a PhD and postdoctoral period from highly-ranked LMU Munich in the lab of nobel-prize for Medicine winner Svante Pääbo in Munich.

Marion is appointed to represent the Federal Ministry for Economic Affairs and Climate Action on the Investment Committe Life Sciences and Chemistry of German Hightech Founders Fund and serves on the Advisory Board of Fox Corporate Finance GmbH.

Record changed: 2024-03-14


Picture Berlin Partner Voices Robinson Data for Precision Medicine 650x200px

More documents for T-Curx GmbH

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]


Picture EBD Group World of Partnering Opportunities 650x300px

» top